[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemodiafiltration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemodiafiltration":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100639360","comparison-of-citrate-and-heparin-anticoagulation-during-postdilution-hemodiafiltration-100639360",false,"NCT07618858","Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration","Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial","CITRA-HDF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End-stage kidney disease requiring maintenance postdilution hemodiafiltration\n* Stable chronic hemodialysis treatment three times weekly\n* Functional arteriovenous fistula\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation therapy\n* Dual antiplatelet therapy\n* Significant coagulopathy\n* Active bleeding\n* Acute kidney injury","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.\n\nThe primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).\n\nSecondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.\n\nTwenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.\n\nThe study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.",[27,28,29,30],"End-Stage Kidney Disease","Hemodiafiltration","Chronic Hemodialysis","Renal Failure",[32,33,28,34,35,36,37,38,39,40,41],"Citrate anticoagulation","Heparin anticoagulation","Dialysis","Biocompatibility","Beta-2 microglobulin","Complement activation","Regional citrate anticoagulation","Chronic dialysis","Thrombin-antithrombin complex","Platelet factor 4","NOT_YET_RECRUITING","2026-05-27",{"date":45,"type":46},"2026-06-01","ACTUAL",{"date":48,"type":21},"2026-06-05",{"date":50,"type":21},"2027-04-01",{"name":52,"class":53},"University Medical Centre Ljubljana","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":73,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":54},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin",{"count":64,"type":21},15,[24],"People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[68,69,70,71,72,28],"End Stage Renal Disease (ESRD)","Chronic Kidney Disease on Hemodialysis","Renal Dialysis","Uremia; Chronic","Hemodialysis",[74,75,76,77,78,79,80,81,82],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","2026-03-23",{"date":85,"type":46},"2026-03-24",{"date":87,"type":21},"2026-04",{"date":89,"type":21},"2029-12",{"name":91,"class":53},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100614390","hemodiafiltration-versus-hemodialysis-in-older-people-100614390","NCT07278973","Hemodiafiltration Versus Hemodialysis in Older People","HemoDiafiltration Versus HemoDialysis in OLDER People: a Randomized, Multicenter, Crossover, Pragmatic Clinical Trial","HD-OLDER","Inclusion Criteria:\n\n* Signed and dated informed consent\n* Age \\>84 years\n* Diagnosed with kidney failure\n* On maintenance hemodialysis \\>3months\n* Willing to have a dialysis session of 3.5 to 4-hour duration, three times a week\n* Has a reliable vascular access\n* Is covered by the health insurance\n\nExclusion Criteria:\n\n* Patients with cognitive impairment (assessed with a mini-test if needed)\n* Hospitalized at inclusion\n* Have difficulties with French speaking\n* Terminally ill with life expectancy\\\u003C3 months\n* With active cancer","85 Years",{"count":102,"type":21},62,[24],"This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF).\n\nPatients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his\u002Fher own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis.\n\nThese two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.",[72,28,106,107,108],"Fatigue Symptom","Quality of Life of Patients","Older People",[72,28,110,111,112,113],"Older people","Fatigue","Patient reported outcome","Dialysis recovery time","RECRUITING","2026-02-20",{"date":117,"type":46},"2026-02-23",{"date":119,"type":21},"2026-02-19",{"date":121,"type":21},"2026-12-19",{"name":123,"class":53},"AUB Santé",4]